4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $631 | -17.4% | 30,044 | +25.4% | 0.00% | – |
| Q1 2024 | $764 | +66.8% | 23,952 | +6.0% | 0.00% | – |
| Q4 2023 | $458 | +67.2% | 22,596 | +5.1% | 0.00% | – |
| Q3 2023 | $274 | -19.9% | 21,490 | +13.6% | 0.00% | – |
| Q2 2023 | $342 | +8.2% | 18,920 | +2.9% | 0.00% | – |
| Q1 2023 | $316 | -18.1% | 18,381 | +5.8% | 0.00% | – |
| Q4 2022 | $386 | -99.7% | 17,379 | -4.0% | 0.00% | – |
| Q3 2022 | $146,000 | +32.7% | 18,108 | +14.7% | 0.00% | – |
| Q2 2022 | $110,000 | -36.0% | 15,790 | +38.8% | 0.00% | – |
| Q1 2022 | $172,000 | -26.5% | 11,375 | +6.6% | 0.00% | – |
| Q4 2021 | $234,000 | -98.1% | 10,675 | -96.2% | 0.00% | -100.0% |
| Q1 2021 | $12,135,000 | -14.8% | 279,746 | -18.6% | 0.00% | 0.0% |
| Q4 2020 | $14,245,000 | – | 343,678 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |